STXI - ETF AI Analysis

Top Page

Strive International Developed Markets ETF (STXI)

Rating:69Neutral

Price Target:―

STXI, the Strive International Developed Markets ETF, earns a solid overall rating driven by high-quality global leaders like Novartis, AstraZeneca, HSBC, and Toyota, all showing strong financial health, positive earnings commentary, and generally supportive valuations or technical trends. Some holdings such as Shell and Nestlé are still financially strong but face challenges like slower revenue or cash flow growth and mixed technical signals, which slightly weigh on the fund’s rating. A key risk factor is the ETF’s meaningful exposure to large financial and healthcare names, which can make performance sensitive to changes in interest rates, regulation, and drug pipelines.

Positive Factors

Broad Country Diversification

The fund spreads its investments across many developed markets like Japan, the UK, the U.S., and several European and Asia-Pacific countries, reducing reliance on any single economy.

Balanced Sector Mix

Holdings are spread across financials, industrials, technology, health care, and other sectors, helping to cushion the impact if one industry struggles.

Improving Recent Performance

The ETF has shown steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.

Negative Factors

Heavy Tilt Toward Financials

A large share of the portfolio is in financial stocks, which can make the fund more sensitive to interest rate changes and banking sector stress.

Mixed Results Among Top Holdings

While some leading positions like ASML and Siemens have performed strongly, others such as SAP, Nestlé, AstraZeneca, and Royal Bank of Canada have been weaker, creating uneven contribution to returns.

Moderate Expense Ratio

The fund’s fee is not especially high but is also not among the cheapest international ETFs, slightly reducing net returns over time.

STXI vs. SPDR S&P 500 ETF (SPY)

AUM22.58M

RegionDeveloped Markets

Expense Ratio0.29%

Beta0.73

IssuerStrive

Inception DateJun 26, 2024

Dividend Yield3.05%

Asset ClassEquity

Index TrackedBloomberg Developed Markets ex US Large & Mid Cap Index - Benchmark TR Net

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,219

30 Day Avg. Volume4,584

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

36.58

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering242

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

STXI Summary

The Strive International Developed Markets ETF (STXI) tracks the Bloomberg Developed Markets ex US Large & Mid Cap Index, giving you broad exposure to stocks in developed countries outside the United States, such as Japan, the UK, and Europe. It owns many well-known companies like Toyota, Nestlé, and ASML, and spreads your money across sectors including financials, industrials, and technology. Someone might invest in STXI to diversify beyond the U.S. market and tap into growth in other major economies. A key risk is that international stock prices can be volatile and move up or down with global markets and currency swings.

How much will it cost me?The Strive International Developed Markets ETF (STXI) has an expense ratio of 0.29%, which means you’ll pay $2.90 per year for every $1,000 invested. This cost is slightly higher than average for ETFs because it is passively managed but focuses on a broad international market niche, which can involve additional complexities compared to U.S.-focused funds.

What would affect this ETF?The Strive International Developed Markets ETF (STXI) could benefit from economic growth in developed markets outside the U.S., particularly if sectors like financials, technology, and healthcare continue to innovate and expand. However, challenges such as rising interest rates, geopolitical tensions, or regulatory changes in key regions could negatively impact its performance, especially for top holdings like ASML, Nestlé, and HSBC that are sensitive to global economic conditions.

STXI Top 10 Holdings

STXI leans heavily on a trio of rising European pharma giants—Roche, Novartis, and AstraZeneca—which have been powering the fund with steady, health-care-driven momentum. ASML adds a punch of high-growth tech flair, helping on the upside when chip demand is in the spotlight. On the financial side, HSBC and Royal Bank of Canada are contributing, though more modestly, while Siemens has been more mixed lately and can occasionally tap the brakes. Overall, this is a developed-markets ex-U.S. play, with strength clustered in Europe and Japan rather than the U.S. megacap crowd.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	2.94%	$663.35K	€438.14B	72.70%	76 Outperform
NOVN	Novartis AG	1.77%	$398.86K	CHF234.59B	22.14%	80 Outperform
ROG	Roche Holding AG	1.76%	$398.26K	CHF272.90B	26.73%	73 Outperform
AZN	AstraZeneca	1.66%	$375.32K	$298.83B	20.11%	80 Outperform
HSBA	HSBC Holdings	1.65%	$372.52K	£213.83B	42.06%	80 Outperform
NESN	Nestlé SA	1.49%	$335.29K	CHF202.95B	0.58%	71 Outperform
SHEL	Shell (UK)	1.34%	$301.50K	£176.52B	22.65%	73 Outperform
7203	Toyota Motor	1.27%	$286.23K	¥45.81T	23.81%	80 Outperform
RY	Royal Bank Of Canada	1.23%	$277.75K	$228.65B	42.10%	75 Outperform
SAP	SAP SE	1.19%	$268.05K	€196.68B	-32.79%	66 Neutral

STXI Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price―

Price Trends

50DMA

32.62

Negative

100DMA

31.40

Positive

200DMA

29.94

Positive

Market Momentum

MACD

-0.04

Positive

RSI

35.30

Neutral

STOCH

9.10

Positive

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For STXI, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 33.40, equal to the 50-day MA of 32.62, and equal to the 200-day MA of 29.94, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.30 is Neutral, neither overbought nor oversold. The STOCH value of 9.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STXI.

STXI Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
STXI	―	―	$22.58M	0.29%	69 Neutral
QLVD	―	―	$61.78M	0.12%	67 Neutral
DEEF	―	―	$56.48M	0.24%	59 Neutral
INEQ	―	―	$54.38M	0.45%	70 Neutral
OEFA	―	―	$38.58M	0.48%	69 Neutral
FFDI	―	―	$18.30M	0.55%	66 Neutral

Performance Comparison

STXI

Strive International Developed Markets ETF

31.76

6.27

24.60%

QLVD

FlexShares Developed Markets ex-US Quality Low Volatility Index Fund

―

DEEF

Xtrackers FTSE Developed ex US Multifactor ETF

―

INEQ

Columbia International Equity Income Etf

―

OEFA

O'Shares International Developed Quality Dividend ETF

―

FFDI

Fidelity Fundamental Developed International ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents